ArticleDiscover oncology2025
SSBP1 is a prognostic biomarker and promotes the progression of lung adenocarcinoma via p53 signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SSBP1, a mitochondrial single-strand binding protein, was found to be significantly overexpressed in lung adenocarcinoma (LUAD) tissues, indicating its potential as a diagnostic biomarker. However, its function in LUAD remained largely unclear. In this study, comprehensive analysis using multiple datasets, including TCGA, GTEx, GSE19188, and GSE63459, consistently demonstrated that SSBP1 expression is elevated in LUAD, distinguishing tumor tissues from normal lung tissues. Moreover, high SSBP1 expression was strongly associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), further supporting its role as a prognostic marker. Multivariate Cox regression analysis confirmed that SSBP1 remains an independent predictor of poor prognosis in LUAD patients. Pan-cancer analysis revealed dysregulated SSBP1 expression across various malignancies, suggesting its involvement in tumorigenesis and its potential as a diagnostic and therapeutic target. Functional studies showed that knockdown of SSBP1 in LUAD cell lines (A549 and H1299) led to significantly reduced proliferation and migration, coupled with downregulation of key cell cycle regulators such as CDK4 and CDK6. Additionally, SSBP1 silencing inhibited LUAD cell metastasis through the p53 signaling pathway, affecting the expression of EMT markers like N-cadherin and E-cadherin. These findings highlight the critical role of SSBP1 in LUAD progression and metastasis, making it a promising therapeutic target for improving LUAD patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.